"TCV-PTC often presents with extrathyroidal extension, lymph node and distant metastases."
"It frequently has vascular invasion, extrathyroidal extension, lymph node metastasis, and distant metastases. The 5-year overall and disease-free survival have been reported to be ~10% lower than that of classic papillary thyroid carcinoma 2, however, this may partly reflect patient age, tumour size, extrathyroidal extension and TNM stage."
"The tall cell is characterised by a height greater than twice its width, eosinophilic cytoplasm, basilar-orientated nuclei, and the classic nuclear features of papillary thyroid carcinoma 1. Tall cell variant PTC can be napsin A positive and is strongly associated with BRAF V600E and often TERT promoter mutations, a combination linked to dedifferentiation ref; tall cell variant morphology frequently forms a component within poorly differentiated or anaplastic thyroid carcinoma."
"The WHO 2022 diagnostic threshold requires at least 30% of tumour cells that are at least three times as tall as they are wide; however, the 30% threshold may not include all tumours with similar aggressive behaviour 5."
"The tall cell is characterised by a height greater than twice its width, eosinophilic cytoplasm, basilar-orientated nuclei, and the classic nuclear features of papillary thyroid carcinoma 1. Tall cell variant PTC can be napsin A positive and is strongly associated with BRAF V600E and often TERT promoter mutations, a combination linked to dedifferentiation ref; tall cell variant morphology frequently forms a component within poorly differentiated or anaplastic thyroid carcinoma."
"There is a lower threshold for total thyroidectomy, central and lateral neck dissection and adjuvant radioiodine. BRAF-TERT mutations may dictate closer subsequent surveillance 5."
"There is a lower threshold for total thyroidectomy, central and lateral neck dissection and adjuvant radioiodine. BRAF-TERT mutations may dictate closer subsequent surveillance 5."
"History and etymology"